Gillian Ivers Read - Jun 1, 2022 Form 4 Insider Report for Clovis Oncology, Inc. (CLVS)

Role
Executive Vice President of Technical Operations and Chief Regulatory Officer
Signature
/s/ Gillian Ivers-Read
Stock symbol
CLVS
Transactions as of
Jun 1, 2022
Transactions value $
-$1,495
Form type
4
Date filed
6/3/2022, 04:15 PM
Previous filing
May 3, 2022
Next filing
Aug 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLVS Common Stock Options Exercise +5.06K +1.82% 284K Jun 1, 2022 Direct F1
transaction CLVS Common Stock Sale -$1.49K -2.33K -0.82% $0.64 282K Jun 2, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Restricted Stock Units Options Exercise $0 +5.06K +10% $0.00 55.7K Jun 1, 2022 Common Stock 5.06K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2 Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3 This transaction was executed in multiple trades at prices ranging from $0.642368 to $0.644300. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 On March 1, 2021, the reporting person was granted 81,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Executive Vice President of Technical Operations and Chief Regulatory Officer